Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (25908)	2/19/2008 1:59:47 PM
From: Biomaven	Respond to of 52153

I thought that innovative companies weren't allowed to go public these days? Well they aren't actually public yet... I've seen quite a few examples of companies (both biotech and non-biotech) being munched in the time after filing but before actually taking the final IPO plunge into the current ice-cold waters. (And I've seen lots of companies being munched just before filing for an IPO). Peter

To: scaram(o)uche who wrote (25908)	2/20/2008 10:57:30 PM
From: tommysdad	Read Replies (1) \| Respond to of 52153

The Tularik/Amgen collaboration's largest effort was on CXCR3, and they actually had a molecule in the clinic that failed in at least two indications. PK was variable, is my understanding. But Amgen continued to work on the target (and the same series of molecules) until at least late 2006 (and may still be working on them for all I know). But more recent literature on CXCR3 suggests the picture of the target is more complicated than originally thought -- KO phenotype improves in scores in some models, worsens in others. Not so different from most chemokines, really, but not my favorite target. (Gee, two posts in two days on companies I follow -- what's up with that?)